Bend Bioscience adds commercial spray drying facility to Georgia site

Ella Day | April 3, 2025 | News story | Manufacturing Services, Manufacturing and Production |  Bend Bioscience, CDMO, Devices, manufacturing, pharma 

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its facility in Gainesville, Georgia, US. The installation process is due to begin immediately.

This addition seeks to support the development of Bend Bioscience’s services, specifically to provide technologically advanced absorption- and bioavailability-enhancement products, and clinical and commercial scale oral dose forms.

The spray suite will feature a GEA PSD-4, a custom-designed, pharma-grade spray dryer. It will also include secondary vacuum drying systems, multiple tank sizes, a dual-stage condenser, and the ability to process highly potent active pharmaceutical ingredients (APIs).

Advertisement

Founded in 2021 and based in Oregon, US, Bend Bioscience is a contract development and manufacturing organisation (CDMO). It provides services to pharma and biotech companies for drug development and manufacturing, focusing on particle engineering and bioavailability enhancement.

Owen Murray, chief executive officer of Bend Bioscience, commented: “These latest additions demonstrate our commitment to providing strong, innovative and comprehensive solutions.”

He added: “It allows us to meet the demands of significant near-term growth through our network of capabilities and expertise in enhancing pharmacokinetics, particle engineering and modified release forms.”

Ella Day
3/4/25

Related Content

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Sterling doubles ADC manufacturing capacity at Welsh facility

Sterling Pharma Solutions has completed a multi-million-pound expansion of its dedicated bioconjugation facility in Deeside, …

Ofichem acquires US drug substance CDMO Kinentia

Ofichem has agreed to acquire Kinentia Biosciences, a US drug substance contract development and manufacturing …

The Gateway to Local Adoption Series

Latest content